Zobrazeno 1 - 10
of 77
pro vyhledávání: '"Chie Emoto"'
Autor:
Chie Emoto, Trevor N. Johnson, David Hahn, Uwe Christians, Rita R. Alloway, Alexander A. Vinks, Tsuyoshi Fukuda
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 5, Pp 273-284 (2019)
Physiologically‐based pharmacokinetic (PBPK) modeling allows assessment of the covariates contributing to the large pharmacokinetic (PK) variability of tacrolimus; these include multiple physiological and biochemical differences among patients. A P
Externí odkaz:
https://doaj.org/article/2417614322424306a3f5384a8e116391
Autor:
Chie Emoto, Trevor N. Johnson, Sibylle Neuhoff, David Hahn, Alexander A. Vinks, Tsuyoshi Fukuda
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 7, Iss 7, Pp 464-473 (2018)
Morphine has large pharmacokinetic variability, which is further complicated by developmental changes in neonates and small infants. The impacts of organic cation transporter 1 (OCT1) genotype and changes in blood‐flow on morphine clearance (CL) we
Externí odkaz:
https://doaj.org/article/6eba7d5d81b146268ee380e8e8eee12d
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 7, Iss 4, Pp 237-250 (2018)
Simultaneous changes in several physiological factors may contribute to the large pharmacokinetic (PK) variability of vancomycin. This study was designed to systematically characterize the effects of multiple physiological factors to the altered PK o
Externí odkaz:
https://doaj.org/article/e7cb8beb6ecf404cba0fdb2882fbf804
Autor:
Chie Emoto, Hirosuke Inoue, Yoshitomo Motomura, Ichiro Ieiri, Tsuyoshi Fukuda, Takaaki Yamada, Shouichi Ohga
Publikováno v:
Therapeutic Drug Monitoring. 44:404-413
Background Teicoplanin is a glycopeptide antibiotic used for the treatment of methicillin-resistant Staphylococcus aureus infections. To ensure successful target attainment, therapeutic drug monitoring-informed dosage adjustment is recommended. Howev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76b472584801de5e463329a27a46021a
https://doi.org/10.1097/ftd.0000000000000930
https://doi.org/10.1097/ftd.0000000000000930
Autor:
Chie, Emoto, Trevor N, Johnson
Publikováno v:
Advances in pharmacology (San Diego, Calif.). 95
Cytochrome P450 enzymes play an important role in the pharmacokinetics, efficacy, and toxicity of drugs. Age-dependent changes in P450 enzyme expression have been studied based on several detection systems, as well as by deconvolution of in vivo phar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::89e8a6250af9c7917a06c7758034296d
https://pubmed.ncbi.nlm.nih.gov/35953161
https://pubmed.ncbi.nlm.nih.gov/35953161
Autor:
Chie Emoto, Brooks T. McPhail, Dawn Butler, Tsuyoshi Fukuda, Henry T. Akinbi, Alexander A. Vinks
Publikováno v:
The Journal of Clinical Pharmacology. 61:857-870
Chronic intrauterine exposure to psychoactive drugs often results in neonatal opioid withdrawal syndrome (NOWS). When nonpharmacologic measures are insufficient in controlling NOWS, morphine, methadone, and buprenorphine are first-line medications co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d877fca2914e35cab79029803b69f3a6
https://doi.org/10.1002/jcph.1811
https://doi.org/10.1002/jcph.1811
Publikováno v:
European Journal of Clinical Pharmacology. 77:1157-1168
Variability in teicoplanin pharmacokinetics has been explained by multiple factors such as body weight, renal function, and serum albumin level. To improve mechanistic understanding of the causes of variability, a physiologically based pharmacokineti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f45d35d4dadda92abe5b511073083b6a
https://doi.org/10.1007/s00228-021-03098-w
https://doi.org/10.1007/s00228-021-03098-w
Autor:
Lisa Neumeier, Kelly McIntosh, Adam S. Nelson, Adam Lane, Min Dong, Tsuyoshi Fukuda, Danielle E. Arnold, Parinda A. Mehta, Federica Achini, Sharat Chandra, Arjan C. Lankester, Alexander A. Vinks, Ashley Teusink-Cross, Chie Emoto, Rebecca A. Marsh, Michael B. Jordan, Kasiani C. Myers, Stella M. Davies
Publikováno v:
Bone Marrow Transplantation. SPRINGERNATURE
Bone Marrow Transplantation
Bone Marrow Transplantation
Alemtuzumab is used as part of reduced-intensity and reduced-toxicity transplant conditioning regimens for nonmalignant diseases. Prior studies identified an ideal target concentration range of 0.15-0.6 mcg/mL at day 0. However, only 24% of patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5077b1484933ad0642391922ff3fd69
https://doi.org/10.1038/s41409-021-01460-1
https://doi.org/10.1038/s41409-021-01460-1
Publikováno v:
Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 51:331-344
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9b3fd4894fcd5357c1d35bbd227f6009
https://doi.org/10.3999/jscpt.51.331
https://doi.org/10.3999/jscpt.51.331
Autor:
Chie EMOTO, Tsuyoshi FUKUDA
Publikováno v:
Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 51:267-276
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c33872ae1ad319629b703b1ebe437c63
https://doi.org/10.3999/jscpt.51.267
https://doi.org/10.3999/jscpt.51.267